{"slug":"tesamorelin","title":"tesamorelin","body":"## Overview\nEvidence is being populated by Grok web search.","register":"standard","tags":[],"category":null,"style":{},"claims":[{"id":"c1","text":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","section":"what_is_known","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair"},{"id":"c2","text":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","section":"what_is_known","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair"},{"id":"c3","text":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","section":"what_is_known","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair"},{"id":"c4","text":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","section":"what_is_known","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair"},{"id":"c5","text":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","section":"what_is_known","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair"}],"sources":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","summary":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","author":"","publisher":"","date":"","claim_ids":["c1"]},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","summary":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","author":"","publisher":"","date":"","claim_ids":["c2"]},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","summary":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","author":"","publisher":"","date":"","claim_ids":["c3"]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","summary":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","author":"","publisher":"","date":"","claim_ids":["c4"]},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","summary":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","author":"","publisher":"","date":"","claim_ids":["c5"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}